Surmodics Enters Into Definitive Agreement to Be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million
May 30, 2024
May 30, 2024
EDEN PRAIRIE, Minnesota, May 30 -- GTCR, a private equity firm, issued the following news release:
Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it has entered into a definitive agreement to be acquired by GTCR, a leading private equity firm with a long track record of investment expertise across healthcare and healthcare technology.
Under the terms of the agreement, aff . . .
Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it has entered into a definitive agreement to be acquired by GTCR, a leading private equity firm with a long track record of investment expertise across healthcare and healthcare technology.
Under the terms of the agreement, aff . . .